American Journal of Psychiatry
Fecha de publicación: 29 July 2019
DOI: https://doi.org/10.1176/appi.ajp.2019.18101212
Autores: Peter Kochunov , Ph.D., Junchao Huang , M.D., Song Chen , M.D., Yanli Li , M.D., Shuping Tan , M.D., Ph.D., Fengmei Fan , Ph.D., Wei Feng , M.D., Yunhui Wang , B.S., Laura M. Rowland , Ph.D., Anya Savransky , B.S., Xiaoming Du , Ph.D., Joshua Chiappelli , M.D., Shuo Chen , Ph.D., et al.
Background: Failure of antipsychotic medications to resolve symptoms in patients with schizophrenia creates a clinical challenge that is known as treatment resistance. The causes of treatment resistance are unknown, but it is associated with earlier age at onset and more severe cognitive deficits. The authors tested the hypothesis that white matter deficits that are involved in both neurodevelopment and severity of cognitive deficits in schizophrenia are associated with a higher risk of treatment resistance.
